Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/24/2024 | $27.00 | Buy | Jefferies |
| 9/24/2024 | $24.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 5/28/2024 | $21.00 | Neutral | Citigroup |
| 4/11/2024 | $18.00 | Underperform | Bernstein |
| 4/3/2024 | Mkt Perform | William Blair | |
| 3/1/2024 | $20.00 | Neutral | Goldman |
| 11/17/2023 | $20.00 | Neutral | Piper Sandler |
| 9/11/2023 | $27.00 | Hold → Buy | Deutsche Bank |
Net Sales Decreased 0.4% to $3.9 Billion; Organic Growth1 was 0.9% Gross Profit Margin Expansion and Our Vue Forward Savings Fuel Increased Marketing Investment Diluted EPS was $0.20; Adjusted Diluted EPS1 was $0.28 Kenvue Inc. (NYSE:KVUE) ("Kenvue"), today announced financial results for the fiscal third quarter ended September 29, 2024. "During the third quarter, we continued to drive strong productivity and realize efficiency benefits from Our Vue Forward, which we are reinvesting behind our iconic brands to unleash the full potential of our business and fulfill our commitment to create long-term shareholder value," said Thibaut Mongon, Chief Executive Officer. "This reinvestment
America's #1 facial skincare1 brand expanding and accelerating collaboration with dermatologists to foster innovation Kenvue Inc. (NYSE: KVUE) ("Kenvue"), the world's largest pure-play consumer health company by revenue, today announced its Neutrogena® brand is taking dermatological beauty to the next level by establishing multi-year partnerships with Dr. Dhaval Bhanusali, renowned skincare innovator, and Dr. Muneeb Shah, the most followed dermatologist worldwide2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241031619557/en/(Photo: Business Wire) This collaboration reinforces Neutrogena®'s commitment to fusing beauty and scie
Starboard Value LP (together with its affiliates, "Starboard" or "we"), today announced that Jeffrey Smith, the firm's Chief Executive Officer and Chief Investment Officer, delivered a presentation at the 2024 Active-Passive Investor Summit to highlight value creation opportunities at three companies: Kenvue Inc. (NYSE:KVUE), Pfizer Inc. (NYSE:PFE) and Salesforce Inc. (NYSE:CRM). The full presentation and the respective presentations for the aforementioned companies can be found at: https://www.starboardvalue.com/presentations. About Starboard Value LP Starboard Value LP is an investment adviser with a focused and differentiated fundamental approach to investing in publicly traded compani
Kathleen Pawlus, Retired Partner and Global Assurance Chief Financial Officer and Chief Operating Officer at EY, and Kirk Perry, Circana President and CEO and Former Procter & Gamble and Google Executive, to Join the Board of Directors Current Johnson & Johnson Executives to Step Down from Kenvue Board of Directors Kenvue Inc. ("Kenvue" or the "Company") (NYSE:KVUE), the world's largest pure-play consumer health company by revenue, today announced the implementation of a Board of Directors ("the Board") succession process, in line with the Company's commitment to best-in-class corporate governance and independent Board oversight. Appointment of Two New Independent Directors to the Boa
Jefferies initiated coverage of Kenvue with a rating of Buy and set a new price target of $27.00
RBC Capital Mkts downgraded Kenvue from Outperform to Sector Perform and set a new price target of $24.00
Citigroup resumed coverage of Kenvue with a rating of Neutral and set a new price target of $21.00
10-Q - Kenvue Inc. (0001944048) (Filer)
8-K - Kenvue Inc. (0001944048) (Filer)
10-Q - Kenvue Inc. (0001944048) (Filer)
Net Sales Decreased 0.4% to $3.9 Billion; Organic Growth1 was 0.9% Gross Profit Margin Expansion and Our Vue Forward Savings Fuel Increased Marketing Investment Diluted EPS was $0.20; Adjusted Diluted EPS1 was $0.28 Kenvue Inc. (NYSE:KVUE) ("Kenvue"), today announced financial results for the fiscal third quarter ended September 29, 2024. "During the third quarter, we continued to drive strong productivity and realize efficiency benefits from Our Vue Forward, which we are reinvesting behind our iconic brands to unleash the full potential of our business and fulfill our commitment to create long-term shareholder value," said Thibaut Mongon, Chief Executive Officer. "This reinvestment
Kenvue Inc. (NYSE:KVUE) ("Kenvue"), the world's largest pure-play consumer health company by revenue, will announce its third quarter 2024 financial results before market open on November 7, 2024. The company will host a conference call and webcast at 8:00 a.m. Eastern Time to discuss its financial results. The conference call can be accessed by dialing 877-407-8835 from the U.S. or +1 201-689-8779 from international locations. A live webcast of the conference call can also be accessed at investors.kenvue.com, with a replay made available after the live event. About Kenvue Kenvue is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage,
Kenvue Inc. (NYSE:KVUE) ("Kenvue"), the world's largest pure-play consumer health company by revenue, today announced that its Board of Directors has declared a quarterly dividend of $0.205 per share on Kenvue's common stock. This quarterly dividend is payable on November 27, 2024, to shareholders of record as of the close of business on November 13, 2024. About Kenvue Kenvue is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we believe
The third quarter dividend is payable on August 28, 2024, to shareholders of record as of the close of business on August 14, 2024.
Throughout the last three months, 4 analysts have evaluated Kenvue (NYSE:KVUE), offering a diverse set of opinions from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 1 3 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 1 0 0 2M Ago 0 0 1 0 0 3M Ago 0 0 1 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $21.0, along with a high estimate of $22.00 and a low estimate of $20.00. Observing a downward trend, the
JP Morgan analyst Andrea Teixeira maintains Kenvue (NYSE:KVUE) with a Overweight and lowers the price target from $23 to $22.
SC 13G/A - Kenvue Inc. (0001944048) (Subject)
SC 13G/A - Kenvue Inc. (0001944048) (Subject)
SC 13G/A - Kenvue Inc. (0001944048) (Subject)
4 - Kenvue Inc. (0001944048) (Issuer)
4 - Kenvue Inc. (0001944048) (Issuer)
3 - Kenvue Inc. (0001944048) (Issuer)